Clinical Cancer Research AACR Conference on Cancer Prevention Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singh, R. P.
Right arrow Articles by Agarwal, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singh, R. P.
Right arrow Articles by Agarwal, R.
Clinical Cancer Research Vol. 10, 244-250, January 2004
© 2004 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

In Vivo Suppression of Hormone-Refractory Prostate Cancer Growth by Inositol Hexaphosphate

Induction of Insulin-Like Growth Factor Binding Protein-3 and Inhibition of Vascular Endothelial Growth Factor

Rana P. Singh, Girish Sharma, G. U. Mallikarjuna, Sivanandhan Dhanalakshmi, Chapla Agarwal and Rajesh Agarwal

Department of Pharmaceutical Sciences, School of Pharmacy and University of Colorado Cancer Center, University of Colorado Health Sciences Center, Denver, Colorado

Purpose: Diet composition is an important etiologic factor in prostate cancer (PCA) growth and has significant impact on clinical PCA appearance. Because inositol hexaphosphate (IP6) is a dietary phytochemical present in cereals, soy, legumes, and fiber-rich foods, we evaluated efficacy of IP6 against PCA growth and associated molecular events.

Experimental Design: DU145 cells were injected into nude mice, and animals were fed normal drinking water or 1 or 2% IP6 in drinking water for 12 weeks. Body weight, diet, water consumption, and tumor sizes were monitored. Tumors were immunohistochemically analyzed for proliferating cell nuclear antigen, terminal deoxynucleotidyl transferase-mediated nick end labeling, and CD31. Tumor-secreted insulin-like growth factor binding protein (IGFBP)-3 and vascular endothelial growth factor (VEGF) were quantified in plasma by ELISA.

Results: IP6 feeding resulted in suppression of hormone-refractory human prostate tumor growth without any adverse effect on body weight gain, diet, and water consumption during entire study. At the end of study, tumor growth inhibition by 1 and 2% IP6 feeding was 47 and 66% (P = 0.049–0.012) in terms of tumor volume/mouse and 40 and 66% (P = 0.08–0.003) in terms of tumor weight/mouse, respectively. Tumor xenografts from IP6-fed mice showed significantly (P < 0.001) decreased proliferating cell nuclear antigen-positive cells but increased apoptotic cells. Tumor-secreted IGFBP-3 levels were also increased up to 1.7-fold in IP6-fed groups. Additionally, IP6 strongly decreased tumor microvessel density and inhibited tumor-secreted VEGF levels.

Conclusions: IP6 suppresses hormone-refractory PCA growth accompanied by inhibition of tumor cell proliferation and angiogenesis and increased apoptosis. IP6-caused increase in IGFBP-3 and decrease in VEGF might have a role in PCA growth control.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
K. Raina, S. Rajamanickam, R. P. Singh, and R. Agarwal
Chemopreventive Efficacy of Inositol Hexaphosphate against Prostate Tumor Growth and Progression in TRAMP Mice
Clin. Cancer Res., May 15, 2008; 14(10): 3177 - 3184.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
Y. Xi, G. Nakajima, T. Hamil, O. Fodstad, A. Riker, and J. Ju
Association of insulin-like growth factor binding protein-3 expression with melanoma progression
Mol. Cancer Ther., December 1, 2006; 5(12): 3078 - 3084.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
R. Veluri, R. P. Singh, Z. Liu, J. A. Thompson, R. Agarwal, and C. Agarwal
Fractionation of grape seed extract and identification of gallic acid as one of the major active constituents causing growth inhibition and apoptotic death of DU145 human prostate carcinoma cells
Carcinogenesis, July 1, 2006; 27(7): 1445 - 1453.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
P. Cohen
Insulin-like growth factor binding protein-3: insulin-like growth factor independence comes of age.
Endocrinology, May 1, 2006; 147(5): 2109 - 2111.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. Liu, K.-W. Lee, H. Li, L. Ma, G. L. Lin, R. A.S. Chandraratna, and P. Cohen
Combination Therapy of Insulin-Like Growth Factor Binding Protein-3 and Retinoid X Receptor Ligands Synergize on Prostate Cancer Cell Apoptosis In vitro and In vivo
Clin. Cancer Res., July 1, 2005; 11(13): 4851 - 4856.
[Abstract] [Full Text] [PDF]


Home page
Integr Cancer TherHome page
M. F. McCarty
Targeting Multiple Signaling Pathways as a Strategy for Managing Prostate Cancer: Multifocal Signal Modulation Therapy
Integr Cancer Ther, December 1, 2004; 3(4): 349 - 380.
[Abstract] [PDF]


Home page
CarcinogenesisHome page
I. Vucenik, A. Passaniti, M. I. Vitolo, K. Tantivejkul, P. Eggleton, and A. M. Shamsuddin
Anti-angiogenic activity of inositol hexaphosphate (IP6)
Carcinogenesis, November 1, 2004; 25(11): 2115 - 2123.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.